Ikarian Capital, LLC Arcus Biosciences, Inc. Transaction History
Ikarian Capital, LLC
- $328 Million
- Q2 2025
A detailed history of Ikarian Capital, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 163,363 shares of RCUS stock, worth $1.58 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
163,363
Previous 163,363
-0.0%
Holding current value
$1.58 Million
Previous $1.28 Million
3.67%
% of portfolio
0.41%
Previous 0.18%
Shares
8 transactions
Others Institutions Holding RCUS
# of Institutions
207Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$94.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$63.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$57.7 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$38.7 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$35.7 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $698M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...